Earlier, we detailed that the syndicate patterns of the most active tech VC investors revealed a host of co-investor relationships, overlapping investing strategies and/or geographic focus areas. But syndicate patterns aren’t limited to tech investing and so we also wanted to take a look at the top investment syndicate partners of 2013’s most active healthcare VCs.
With the healthcare market seeing a big year on the IPO front in 2013, there were number of highly active venture capital investors pursuing deals in healthcare (biotech, pharma, drug, medical devices). Based on unique company investments, Versant Ventures and New Enterprise Associates, topped the list of most active U.S.-based VCs in the healthcare sector. The top 3 was rounded out by Domain Associates (which was among the top healthcare VCs ranked by 2013 IPOs).
The chart below highlights the most frequent co-investment partners in 2013 of each of the 10 most active healthcare VCs identified above. Similar to the most active tech VCs, healthcare’s most active investors also see a presence of corporate venture arms among their top syndicate partners including Johnson & Johnson Development Corporation and GlaxoSmithKline’s SR One. The chart also reveals several co-investment relationships with the healthcare investment arms of PE firms and mutual funds including TPG Biotech and Fidelity Biosciences.
This report was created with data from CB Insights’ emerging technology insights platform, which offers clarity into emerging tech and new business strategies through tools like:
- Earnings Transcripts Search Engine & Analytics to get an information edge on competitors’ and incumbents’ strategies
- Patent Analytics to see where innovation is happening next
- Company Mosaic Scores to evaluate startup health, based on our National Science Foundation-backed algorithm
- Business Relationships to quickly see a company’s competitors, partners, and more
- Market Sizing Tools to visualize market growth and spot the next big opportunity